Download PDF
Aktuelle Neurologie 2001; 28(2): 62-73
DOI: 10.1055/s-2001-11300
ÜBERSICHT
Übersicht
© Georg Thieme Verlag Stuttgart · New York

Atypische Neuroleptika und neue Antidepressiva in der Therapie neurologischer Erkrankungen

A. Bayas1 , J. Kornhuber2 , M. Naumann1
  • 1Neurologische Universitätsklinik Würzburg
  • 2Psychiatrische Universitätsklinik Erlangen
Further Information

Publication History

Publication Date:
31 December 2001 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Atypische Neuroleptika und neue Antidepressiva unterscheiden sich von den klassischen Präparaten durch unterschiedliche Wirkmechanismen und zum Teil günstigere Nebenwirkungsspektren. Wenngleich sie primär zur Therapie psychiatrischer Erkrankungen zum Einsatz kommen, führte vor allem dieses günstige Nebenwirkungsprofil zum Einsatz der Präparate auch bei neurologischen Erkrankungen, bei denen die Anwendung älterer Substanzen, wie trizyklische Antidepressiva, oft mit intolerablen Nebenwirkungen verbunden war. So wurden atypische Neuroleptika, wie Clozapin, erfolgreich zur Behandlung L-Dopa-induzierter Psychosen beim M. Parkinson eingesetzt, ohne extrapyramidale Symptome zu verschlechtern. Neue Antidepressiva, wie Fluoxetin, zeigten sich unter anderem bei der Behandlung der Affektinkontinenz als wirksam. Der vorliegende Artikel soll einen Überblick über den Einsatz atypischer Neuroleptika und neuer Antidepressiva (fokussiert auf die selektiven Serotoninwiederaufnahmehemmer) zur Behandlung neurologischer Krankheiten geben.

Atypical Neuroleptics and New Antidepressants in the Treatment of Neurological Disorders

Compared to the classical drugs, atypical neuroleptics and new antidepressants are characterised by different mechanisms of action and, in a number of aspects, by a more favourable side effect profile. Though primarily applied in psychiatric disorders these properties prompted their use in neurological diseases, where side effects of classical therapeutics, such as tricyclic antidepressants, are often a major concern. For example, atypical neuroleptics, like clozapine, were successfully applied for the treatment of l-dopa-induced psychosis in Parkinson's disease without deterioration of motor functions. New antidepressants, like fluoxetine, have been shown to be effective in emotionalism. This article provides an overview of the use of atypical neuroleptics and new antidepressants (focused on selective serotonin reuptake inhibitors) in the treatment of neurological disorders.

Literatur

  • 1 Riedel M, Müller N, Möller H-J. Atypische Neuroleptika.  Akt Neurol. 2000;  27 340-348
    PubMedGoogle Scholar
  • 2 Scholz E, Dichgans J. Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine.  Eur Arch Psychiatry Neurol Sci. 1985;  235 60-64
    CrossrefPubMedGoogle Scholar
  • 3 Greene P, Coté L, Fahn S. Treatment of drug-induced psychosis in Parkinson's disease with clozapine.  Adv Neurol. 1993;  60 703-706
    PubMedGoogle Scholar
  • 4 Koller W C, Pahwa R, Lyons K, Smith D. Low dose clozapine in the treatment of levodopa induced psychosis (abstract).  Mov Disord. 1994;  9 64
    CrossrefPubMedGoogle Scholar
  • 5 Rabey JM,Trevas T A, Orlov E. et al . Low dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson's disease.  Neurology. 1995;  45 432-434
    PubMedGoogle Scholar
  • 6 Factor S A, Molho E S, Podskalny G D, Brown D. Parkinson's disease: drug-induced psychiatric states.  Adv Neurol. 1995;  65 115-138
    PubMedGoogle Scholar
  • 7 Factor S A, Friedman J H. The emerging role of clozapine in the treatment of movement disorders.  Mov Disord. 1997;  12 483-496
    CrossrefPubMedGoogle Scholar
  • 8 Retz W, Rösler M, Sitzmann L, Becker T. Clozapin in der Behandlung neuropsychiatrischer Erkrankungen im Alter.  Fortschr Neurol Psychiatrie. 1997;  65 347-353
    PubMedGoogle Scholar
  • 9 Trosch R T, Friedman J H, Lannon M C. et al . Clozapine use in Parkinson's disease: A retrospective analysis of a large multicentered clinical experience.  Mov Disord. 1998;  13 377-382
    CrossrefPubMedGoogle Scholar
  • 10 Wolters E C. Dopaminomimetic psychosis in Parkinson's disease patients.  Neurology. 1999;  52 S10-13
    PubMedGoogle Scholar
  • 11  The French Clozapine Study Group. Clozapine in drug-induced psychosis in Parkinson's disease.  Lancet. 1999;  353 2041-2042
    CrossrefPubMedGoogle Scholar
  • 12  The Parkinson study group. Low dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease.  N Engl J Med. 1999;  340 757-763
    CrossrefPubMedGoogle Scholar
  • 13 Wolters E C, Hurwitz T A, Mak E. et al . Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis.  Neurology. 1990;  40 832-834
    PubMedGoogle Scholar
  • 14 Pakkenberg H, Pakkenberg B. Clozapine in the treatment of tremor.  Acta Neurol Scand. 1986;  73 295-297
    PubMedGoogle Scholar
  • 15 Fischer P A, Baas H, Hefner R. Treatment of parkinsonian tremor with clozapine.  J Neural Trans. 1990;  2 223-228
    PubMedGoogle Scholar
  • 16 Friedman J H, Lannon M C. Clozapine-responsive tremor in Parkinson's disease.  Mov Disord. 1990;  5 225-265
    CrossrefPubMedGoogle Scholar
  • 17 Bonucelli U, Ceravolo R, Salvetti S. et al . Clozapine in Parkinson's disease tremor. Effect of acute and chronic administration.  Neurology. 1997;  49 1587-1590
    PubMedGoogle Scholar
  • 18 McCarthy R H. Clozapine reduces essential tremor independent of its antipsychotic effect. A case report.  J Clin Pharmacol. 1994;  12 212-213
    PubMedGoogle Scholar
  • 19 Ceravolo R, Salvetti S, Piccini P. Acute and chronic effects of clozapine in essential tremor.  Mov Disord. 1999;  14 468-472
    CrossrefPubMedGoogle Scholar
  • 20 Delecluse F, Elosegi J A, Gérard J. A case of tardive tremor sucessfully treated with clozapine.  Mov Disord. 1998;  13 846
    CrossrefPubMedGoogle Scholar
  • 21 Miller C H, Mohr F, Umbricht D. et al . The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics.  J Clin Psychiatry. 1998;  59 69-75
    PubMedGoogle Scholar
  • 22 Kane J, Honigsfeld G, Singer J. et al . Clozapine for the treatment-resistant schizophrenic.  Arch Gen Psychiatry. 1988;  45 789-796
    PubMedGoogle Scholar
  • 23 Lieberman J A, Saltz B L, Johns C A. et al . The effects of clozapine on tardive dyskinesia.  Br J Psychiatry. 1991;  158 503-510
    PubMedGoogle Scholar
  • 24 Tamminga C A, Thaker G K, Moran M. et al . Clozapine in tardive dyskinesia: observations from human and animal model studies.  J Clin Psychiatry. 1994;  55 102-106
    PubMedGoogle Scholar
  • 25 Bonucelli U, Ceravolo R, Maremmani C. et al . Clozapine in Huntington's disease.  Neurology. 1994;  44 821-823
    PubMedGoogle Scholar
  • 26 van Vugt J PP, Siesling S, Vergeer M. et al . Clozapine versus placebo in Huntington's disease (abstract).  Mov Disord. 1996;  11 54
    PubMedGoogle Scholar
  • 27 Benett J P, Landow E R, Schuh L A. Suppression of dyskinesias in advanced Parkinson's disease.  Neurology. 1993;  43 1551-1555
    PubMedGoogle Scholar
  • 28 Caine E D, Jolinsky R J, Kartzinel J. et al . The trial use of clozapine for abnormal involuntary movement disorder.  Am J Psychiatry. 1979;  136 317-320
    PubMedGoogle Scholar
  • 29 Thiel A, Dressler D, Kistel C, Rüther E. Clozapine treatment of spasmodic torticollis.  Neurology. 1994;  44 957-958
    PubMedGoogle Scholar
  • 30 Miller D D, Sharafuddin M JA, Kathol R G. A case of clozapine induced neurolpetic malignant syndrome.  J Clin Psychiatry. 1991;  52 99-101
    PubMedGoogle Scholar
  • 31 Beasley C M, Tollefson G D, Tran P V. et al . Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.  Neuropsychopharmacology. 1996;  14 111-123
    CrossrefPubMedGoogle Scholar
  • 32 Tran P V, Dellva M A, Tollefson G D. et al . Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia.  J Clin Psychiatry. 1997;  58 205-211
    PubMedGoogle Scholar
  • 33 Wolters E C, Jansen E NH, Tuynman-Qua H G, Bergmans B ML. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease.  Neurology. 1996;  47 1085-1087
    CrossrefPubMedGoogle Scholar
  • 34 Aarsland D, Larsen J P, Lim N G, Tandberg E. Olanzapine for psychosis in patients with Parkinson's disease with and without dementia.  J Neuropsychiatry Clin Neurosci. 1999;  11 392-394
    PubMedGoogle Scholar
  • 35 Walker Z, Grace J, Overshot R. et al . Olanzapine in dementia with lewy bodies: a clinial study.  Int J Geriatr Psychiatry. 1999;  14 459-466
    PubMedGoogle Scholar
  • 36 Graham J, Sussman J D, Ford K S, Sagar H J. Olanzapine in the treatment of hallucinosis in idiopathic Parkinson's disease: a cautionary note.  J Neurol Neurosurg Psychiatry. 1998;  65 774-777
    PubMedGoogle Scholar
  • 37 Friedmann J. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease (letter).  Neurology. 1998;  50 1195-1196
    PubMedGoogle Scholar
  • 38 Jiménez-Jiménez F J, Tallón-Barranco A, Orti-Parejy M. et al . Olanzapine can worsen parkinsonism.  Neurology. 1998;  50 1183-1184
    PubMedGoogle Scholar
  • 39 Friedman J H, Goldstein S, Jacques C. Substituting clozapine for olanzapine in psychiatrically stable Parkinson's disease patients: results of an open label pilot study.  Clin Neuropharmacol. 1998;  21 285-288
    PubMedGoogle Scholar
  • 40 Molho E S, Factor S A. Worsening of motor features of parkinsonism with olanzapine.  Mov Disord. 1999;  14 1014
    CrossrefPubMedGoogle Scholar
  • 41 Strauss A J, Bailey R K, Dralle P W. et al . Conventional psychotropic-induced tremor extinguished by olanzapine (letter).  Am J Psychiatry. 1998;  155 1132
    PubMedGoogle Scholar
  • 42 Soutullo C, Keck P, McElroy S. Olanzapine in the treatment of tardive dyskinesia. A report of two cases.  J Clin Psychopharmacol. 1999;  19 100-101
    CrossrefPubMedGoogle Scholar
  • 43 Fulton B, Goa K L. Olanzapine. A review of ist pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses.  Drugs. 1997;  53 281-298
    CrossrefPubMedGoogle Scholar
  • 44 Filice G A, McDougall B C, Ercan-Fang N, Billington C. Neuroleptic malignant syndrome associated with olanzapine.  Ann Pharmacother. 1998;  32 1158-1159
    PubMedGoogle Scholar
  • 45 Chouinard G, Jones B, Remington G. et al . A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophenic patients.  J Clin Psychopharmacol. 1993;  13 25-40
    PubMedGoogle Scholar
  • 46 Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multinational, multi-centre, double blind, parallel group study versus haloperidol.  Br J Psychiatry. 1995;  166 712-726
    CrossrefPubMedGoogle Scholar
  • 47 Gwinn K A, Caviness J N. Risperidone-induced tardive dyskinesia and Parkinsonism.  Mov Disord. 1997;  12 119-121
    PubMedGoogle Scholar
  • 48 Addington D E, Toews J A, Addington J M. Risperidone and tardive dyskinesia: a case report.  J Clin Psychiatry. 1995;  56 484-485
    PubMedGoogle Scholar
  • 49 Friedman J H, Ott B. Should Risperidone be used in Parkinson's disease?.  J Neuropsychiatry Clin Neurosci. 1998;  10 473-474
    PubMedGoogle Scholar
  • 50 Meco G, Allesandri A, Bonifati V, Giustini P. Risperidone for hallucinations in levodopa-treated Parkinson's disease patients.  Lancet. 1994;  343 1370-1371
    PubMedGoogle Scholar
  • 51 Workman R H, Orengo C, Bakey A. et al . The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease.  J Neuropsychiatry Clin Neurosci. 1997;  9 594-597
    PubMedGoogle Scholar
  • 52 Meco G, Alessandri A, Giustini P, Bonifati V. Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: an open-label long-term study.  Mov Disord. 1997;  12 610-612
    CrossrefPubMedGoogle Scholar
  • 53 Ford B, Lynch T, Greene P. Risperidone in Parkinson's disease (letter).  Lancet. 1994;  344 681
    PubMedGoogle Scholar
  • 54 Rich S, Fridman J H, Ott B. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes.  J Clin Psychiatry. 1995;  56 556-559
    PubMedGoogle Scholar
  • 55 McKeith I G, Ballard C G, Harrison R WS. Neuroleptic sensitivity to risperidone in Lewy body dementia.  Lancet. 1995;  346 699
    CrossrefPubMedGoogle Scholar
  • 56 Allen R L, Walker Z, D'Ath P J, Katona C LE. Risperidone for psychotic and behavioural problems in Lewy body dementia (letter).  Lancet. 1995;  346 185
    CrossrefPubMedGoogle Scholar
  • 57 Geizer M, Ancill R J. Combination of risperidone and donazepil in Lewy body dementia.  Can J Psychiatry. 1998;  43 421-422
    PubMedGoogle Scholar
  • 58 van der L inden, Bruggeman R, van Woerkom T. Risperidone in the treatment of Gille de la Tourette's syndrome (abstract).  Ann Neurol. 1993;  34 263
    PubMedGoogle Scholar
  • 59 Shulman L, Singer C, Weiner W. Risperidone in Gilles de la Tourette syndrome.  Neurology. 1995;  45 1419
    PubMedGoogle Scholar
  • 60 Bruun R D, Budman C L. Risperidone as a treatment for Tourette's syndrome.  J Clin Psychiatry. 1996;  57 29-31
    PubMedGoogle Scholar
  • 61 Chouinard G. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study.  J Clin Psychopharmacol. 1995;  15 36S-44S
    PubMedGoogle Scholar
  • 62 Evidente V, Gwinn-Hardy K, Caviness J. Risperidone is effective in severe hemichorea/hemiballism.  Mov Disord. 1999;  14 377-379
    CrossrefPubMedGoogle Scholar
  • 63 Meco G, Bonifati V, Alessandri A. et al . Risperidone in Huntington's diesease (letter).  Human Psychopharmacol. 1995;  10 353-354
    PubMedGoogle Scholar
  • 64 Reveley M A, Dursum S M, Andrews H A. Comparative use of sulpirid and risperidone in Huntington's disease: a pilot study.  J Psychopharmacol. 1996;  10 162-165
    PubMedGoogle Scholar
  • 65 Zuddas A, Cianchetti C. Efficacy of risperidone in idiopathic segmental dystonia (letter).  Lancet. 1996;  347 127-128
    CrossrefPubMedGoogle Scholar
  • 66 Dave M. Two cases of risperidone-induced neuroleptic malignant syndrome.  Am J Psychiatry. 1995;  152 1233-1244
    PubMedGoogle Scholar
  • 67 Bajjoka I. Risperidone-induced neuroleptic malignant syndrome.  Ann Emerg Med. 1997;  30 698-700
    PubMedGoogle Scholar
  • 68 Luckhaus C, Müller W. Quetiapin, ein neues atypisches Neuroloptikum.  Psychopharmakotherapie. 2000;  2 63-69
    PubMedGoogle Scholar
  • 69 Fernandez H H, Friedmann J H, Jacques C, Rosenfeld M. Quetiapine for the treatment of drug-induced psychosis in parkinson's disease.  Mov Disord. 1999;  14 484-487
    CrossrefPubMedGoogle Scholar
  • 70 Friedmann J H, Steward A F. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease.  Mov Disord. 2000;  15 201-211
    CrossrefPubMedGoogle Scholar
  • 71 Fagius J, Osterman P O, Sidén Å, Wiholm B-E. Guillain-Barré syndrome following zimeldine treatment.  J Neurol Neurosurg Psychiatry. 1985;  48 65-69
    PubMedGoogle Scholar
  • 72 Songer D A, Schulte H. Venlafaxine for the treatment of chronic pain (letter).  Am J Psychiatry. 1996;  153 737
    PubMedGoogle Scholar
  • 73 Taylor K, Rowbotham M C. Venlafaxine hydrochloride and chronic pain.  WJM. 1996;  165 147-148
    PubMedGoogle Scholar
  • 74 Brannon G E, Stone K D. The use of mirtazapine in a patient with chronic pain.  J Pain Symptom Manage. 1999;  18 382-385
    CrossrefPubMedGoogle Scholar
  • 75 Davis J L, Smith R L. Painful peripheral diabetic neuropathy treated with venlafaxine HCl extended release capsules (letter).  Diabetes care. 1999;  22 1909-1910
    PubMedGoogle Scholar
  • 76 Pact V, Giduz T. Mirtazapine treats resting tremor, essential tremor, and levodopa-induced dyskinesias.  Neurology. 1999;  53 1154
    PubMedGoogle Scholar
  • 77 Mirzaian E, Gastpar M. Neue Antidepressiva.  Akt Neurol. 2000;  27 132-137
    PubMedGoogle Scholar
  • 78 Robinson R G. Treatment issues in poststroke depression.  Depression and anxiety. 1998;  8, Suppl 1 85-90
    CrossrefPubMedGoogle Scholar
  • 79 Teasell R W, Merskey H, Deshpande S. Antidepressants in rehabilitation.  Phys Med Rehabil Clin N Am. 1999;  10 237-253
    PubMedGoogle Scholar
  • 80 Ramasubbu R, Flint A, Brown G. et al . Diminished serotonin-mediated prolactin responses in nondepressed stroke patients compared with healthy normal subjects.  Stroke. 1998;  29 1293-1298
    PubMedGoogle Scholar
  • 81 Stamenkovic M, Schindler S, Kasper S. Therapie der Poststroke-Depression mit Fluoxetin.  Nervenarzt. 1996;  67 62-67
    PubMedGoogle Scholar
  • 82 Andersen G, Vestergaard K, Lauritzen L. Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram.  Stroke. 1994;  25 1099-1104
    PubMedGoogle Scholar
  • 83 Dam M, Tonin P, De Boni A. et al . Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy.  Stroke. 1996;  27 1211-1214
    PubMedGoogle Scholar
  • 84 Robinson R G, Schultz S K, Castillo C. et al . Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study.  Am J Psychiatry. 2000;  157 351-359
    CrossrefPubMedGoogle Scholar
  • 85 Wiart L, Petit H, Joseph P A. et al . Fluoxetine in early poststroke depression: a double-blind placebo-controlled study.  Stroke. 2000;  31 1829-1832
    PubMedGoogle Scholar
  • 86 Andersen G. Treatment of uncontrolled crying after stroke.  Drugs Aging. 1995;  6 105-111
    PubMedGoogle Scholar
  • 87 Andersen G, Vestergaard K, O Riis J. Citalopram for post-stroke pathological crying.  Lancet. 1993;  342 837-839
    CrossrefPubMedGoogle Scholar
  • 88 Brown K W, Sloan R L, Pentland B. Fluoxetine as a treatment for post-stroke emotionalism.  Acta Psychiatr Scand. 1998;  98 455-458
    PubMedGoogle Scholar
  • 89 Burns A, Russell E, Stratton-Powell H. et al . Sertraline in stroke-associated lability of mood.  Int J Geriat Psychiatry. 1999;  14 681-685
    CrossrefPubMedGoogle Scholar
  • 90 Müller U, Murai T, Bauer-Wittmund T, von Cramon D Y. Paroxetine versus citalopram treatment of pathological crying after brain injury.  Brain Inj. 1999;  13 805-811
    CrossrefPubMedGoogle Scholar
  • 91 Hanger H C. Emotionalism after stroke (letter).  Lancet. 1993;  342 1235-1236
    CrossrefPubMedGoogle Scholar
  • 92 Iannaccone S, Ferini-Strambi L. Pharmacological treatment of emotional lability.  Clin Neuropharmacol. 1996;  19 532-535
    PubMedGoogle Scholar
  • 93 Seliger G M, Hornstein A, Flax J. et al . Fluoxetine improves emotional incontinence.  Brain injury. 1992;  6 267-270
    PubMedGoogle Scholar
  • 94 Derex L, Ostrowsky K. Severe pathological crying after left anterior choroidal artery infarct. Reversibility with paroxetine treatment.  Stroke. 1997;  28 1464-1466
    PubMedGoogle Scholar
  • 95 Nahas Z, Arlinghaus K A, Kotrla K J. et al . Rapid response of emotional incontinence to selective serotonin reuptake inhibitors.  J Neuropsy Clin Neurosci. 1998;  10 453-455
    PubMedGoogle Scholar
  • 96 Schachter M, Parkes J D. Fluvoxamine and clomipramine in the treatment of cataplexy.  J Neurol Neurosurg Psychiatry. 1980;  43 171-174
    CrossrefPubMedGoogle Scholar
  • 97 Langdon N, Shindler J, Parkes J D, Bandak S. Fluoxetine in the treatment of cataplexy (letter).  Sleep. 1986;  9 371-373
    PubMedGoogle Scholar
  • 98 Frey J, Darbonne C. Fluoxetine suppresses human cataplexy: a pilot study.  Neurology. 1994;  44 707-709
    PubMedGoogle Scholar
  • 99 Sindrup S H, Bjerre U, Dejgaard A. et al . The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy.  Clin Pharmacol Ther. 1992;  52 547-552
    PubMedGoogle Scholar
  • 100 Sindrup S H, Gram L F, Brosen K. et al . The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms.  Pain. 1990;  42 135-144
    CrossrefPubMedGoogle Scholar
  • 101 Sindrup S H, Grodum E, Gram L F, Beck-Nielsen H. Concentration-response relationship in paroxetine treatment of diabetic neuropathy symptoms: a patient-blinded dose-escalation study.  Ther Drug Monit. 1991;  13 408-414
    PubMedGoogle Scholar
  • 102 Max M B, Lynch S A, Muir J. et al . Effects of desipramine, amitriptyline and fluoxetine on pain in diabetic neuropathy.  New Engl J Med. 1992;  326 1250-1256
    CrossrefPubMedGoogle Scholar
  • 103 Goodnick P J, Jimenez I, Kumar A. Sertraline in diabetic neuropathy: preliminary results.  Ann Clin Psychiatry. 1997;  9 255-257
    CrossrefPubMedGoogle Scholar
  • 104 Adly C, Straumanis J, Chesson A. Fluoxetine prophylaxis of migraine.  Headache. 1992;  32 101-104
    CrossrefPubMedGoogle Scholar
  • 105 Bank J. A comparative study of amitriptyline and fluvoxamine in migraine prophylaxis.  Headache. 1994;  34 476-478
    CrossrefPubMedGoogle Scholar
  • 106 Saper J R, Silberstein S D, Lake A E, Winters M E. Double-blind trial of fluoxetine: chronic daily headache and migraine.  Headache. 1994;  34 497-502
    CrossrefPubMedGoogle Scholar
  • 107 Manna V, Bolino F, Di Cicco L. Chronic tension-type headache, mood depression and serotonin: therapeutic effects of fluvoxamine and mianserin.  Headache. 1994;  34 44-49
    CrossrefPubMedGoogle Scholar
  • 108 Langemark M, Olesen J. Sulpiride and paroxetine in the treatment of chronic tension-type headache. An explanatory double-blind trial.  Headache. 1994;  34 20-24
    CrossrefPubMedGoogle Scholar
  • 109 Bendtsen L, Jensen R, Olesen J. A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache.  J Neurol Neurosurg Psychiatry. 1996;  61 285-290
    CrossrefPubMedGoogle Scholar
  • 110 Goldenberg D, Mayskiy M, Mossey C. et al . A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia.  Arthritis Rheum. 1996;  39 1852-1859
    PubMedGoogle Scholar
  • 111 Wolfe F, Cathey M A, Hawley D J. A double-blind placebo controlled trial of fluoxetine in fibromyalgia.  Scand J Rheumatol. 1994;  23 255-259
    PubMedGoogle Scholar
  • 112 Nørregaard J, Volkmann H, Danneskiold-Samsøe B. A randomized controlled trial of citalopram in the treatment of fibromyalgia.  Pain. 1995;  61 445-449
    CrossrefPubMedGoogle Scholar
  • 113 Smith A J. The analgesic effects of selective serotonin reuptake inhibitors.  J Psychopharmacol. 1998;  12 407-413
    PubMedGoogle Scholar
  • 114 Rani P U, Naidu M UR, Prasad V BN. et al . An evaluation of antidepressants in rheumatic pain conditions.  Anesth Analg. 1996;  83 371-375
    PubMedGoogle Scholar
  • 115 Scatton B, Javoy-Agid F, Rouquier L. et al . Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease.  Brain Res. 1983;  275 321-328
    CrossrefPubMedGoogle Scholar
  • 116 Mayeux R, Stern Y, Cote L, Williams J BW. Altered serotonin metabolism in depressed patients with Parkinson's disease.  Neurology. 1984;  34 642-646
    PubMedGoogle Scholar
  • 117 Richard I H, Kurlan R,  and the Parkinson Study Group. A survey of antidepressant drug use in Parkinson's disease.  Neurology. 1997;  49 1168-1170
    PubMedGoogle Scholar
  • 118 Chase T N, Ng L KY, Watanabe A M. Parkinson's disease. Modification by 5-hydroxytryptophan.  Neurology. 1972;  22 479-484
    PubMedGoogle Scholar
  • 119 Valldeoriola F, Nobbe F A, Tolosa E. Treatment of behavioural disturbances in Parkinson's disease.  J Neural Transm. 1997;  51, Suppl 175-204
    PubMedGoogle Scholar
  • 120 Poewe W, Luginger E. Depression in Parkinson's disease. Impediments to recognition and treatment options.  Neurology. 1999;  52 S2-S6
    PubMedGoogle Scholar
  • 121 Cummings J L, Masterman D L. Depression in patients with Parkinson's disease.  Int J Geriat Psychiatry. 1999;  14 711-718
    CrossrefPubMedGoogle Scholar
  • 122 McCance-Katz E F, Marek K L, Price L H. Serotonergic dysfunction in depression associated with Parkinson's disease.  Neurology. 1992;  42 1813-1814
    PubMedGoogle Scholar
  • 123 Hauser R A, Zesiewicz T A. Sertraline for the treatment of depression in Parkinson's disease.  Mov Disord. 1997;  12 756-759
    CrossrefPubMedGoogle Scholar
  • 124 Meara J, Hobson P. Sertraline for the treatment of depression in Parkinson's disease (letter).  Mov Disord. 1998;  13 622
    CrossrefPubMedGoogle Scholar
  • 125 Grubb B P, Samoil D, Kosinski D. et al . Fluoxetine hydrochloride for the treatment of severe refractory orthostatic hypotension.  Am J Med. 1994;  97 366-368
    CrossrefPubMedGoogle Scholar
  • 126 Montastruc J L, Pelat M, Verwaerde P. et al . Fluoxetine in orthostatic hypotension of Parkinson's disease: a clinical and experimental pilot study.  Fundam Clin Pharmacol. 1998;  12 398-402
    PubMedGoogle Scholar
  • 127 Durif F, Vidailhet M, Bonnet A M. et al . Levodopa-induced dyskinesias are improved by fluoxetine.  Neurology. 1995;  45 1855-1858
    PubMedGoogle Scholar
  • 128 Montastruc J-L, Fabre N, Blin O. et al . Does fluoxetine aggravate Parkinson's disease? A pilot prospective study.  Mov Disord. 1995;  10 355-357
    CrossrefPubMedGoogle Scholar
  • 129 Caley C F, Friedman J H. Does fluoxetine exacerbate Parkinson's disease?.  J Clin Psychiatry. 1992;  53 278-282
    PubMedGoogle Scholar
  • 130 Leo R J. Movement disorders associated with the serotonin selective reuptake inhibitors.  J Clin Psychiatry. 1996;  57 449-454
    CrossrefPubMedGoogle Scholar
  • 131 Bouchard R H, Pourcher E, Vincent P. Fluoxetine and extrapyramidal side effects (letter).  Am J Psychiatry. 1989;  146 1352-1353
    PubMedGoogle Scholar
  • 132 Richard I H, Maughn A, Kurlan R. Do serotonin reuptake inhibitor antidepressants worsen Parkinson's disease? A retrospective case series.  Mov Disord. 1999;  14 155-157
    CrossrefPubMedGoogle Scholar
  • 133 Sternbach H. The serotonin syndrome.  Am J Psychiatry. 1991;  148 705-713
    PubMedGoogle Scholar
  • 134 Toyama S C, Iacono R P. Is it safe to combine a selective serotonin reuptake inhibitor with selegeline (letter)?.  Ann Pharmacother. 1994;  28 405-406
    PubMedGoogle Scholar
  • 135 Kasper S, Möller H-J, Müller-Spahn F. Depression: Diagnose und Pharmakotherapie. Stuttgart, New York; Thieme 1997
    Google Scholar
  • 136 Nelson J G. Safety and tolerability of the new antidepressants.  J Clin Psychiatry. 1997;  58, Suppl 6 26-31
    PubMedGoogle Scholar
  • 137 Edwards J G, Anderson I. Systematic review and guide to selection of selective serotonin reuptake inhibitors.  Drugs. 1999;  57 507-533
    CrossrefPubMedGoogle Scholar
  • 138 Caley C F. Extrapyramidal reactions and the selective serotonin-reuptake inhibitors.  Ann Pharmacother. 1997;  31 1481-1489
    PubMedGoogle Scholar
  • 139 Gerber P E, Lynd L D. Selective serotonin-reuptake inhibitor-induced movement disorders.  Ann Pharmacother. 1998;  32 692-698
    CrossrefPubMedGoogle Scholar
  • 140 Lane R M. SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment.  J Psychopharmacol. 1998;  12 192-214
    PubMedGoogle Scholar

PD Dr. Markus Naumann

Neurologische Universitätsklinik der Bayerischen Julius-Maximilians-Universität Würzburg

Josef-Schneider-Str. 11

97080 Würzburg

Email: naumann@mail.uni-wuerzburg.de

      >